ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > New Press Release - ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von May 08, 2023 2:21pm

119 Views

Post# 35436863

RE:RE:RE:RE:New Press Release - ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

bball67 wrote: My conjecture is it will be in 2-3 months, when 1a trial is completed, thus clearing the deck for an offering. At that point the stock should have built a good base at a slightly higher level than now. Don't assume that an offering would be at lower levels. There could be a 10x demand for the stock which drives the price up, like an IPO. The Boston group will put in $10M or possibly more and own 50%+ of Promis. Offering size of $20-30M. This is all conjecture on my part.

An offering better be at a level of a lot more than $30M. And the Boston Group owning a 50%+ of ProMis. I can't see that with only putting in $10M. And you wouldn't what them owning a majority interest in the stock.

I'm also in the conjecture territory. :)

G1945V

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?